Mereo BioPharma(MREO)

Focus: Mereo BioPharma is a UK-based public biotech focused on acquiring and rapidly developing drugs across oncology, endocrinology, women's health, respiratory, and nephrology. The company operates a lean, acquisition-driven model with a diversified pipeline of 50+ programs.

Oncology Endocrinology Women's Health Respiratory

Profile data last refreshed 1h ago · AI intelligence enriched 2mo ago

Funding Stage

PUBLIC

Open Jobs

About Mereo BioPharma

AI assessmentNot Hiring

No open roles listed right now. Follow Mereo BioPharma to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

3/9 — Basic

Company HealthSolid

Pipeline

Early-stage

50 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Revenue

$0K

FY2025

Pipeline & Clinical Trials

OMP-305B83

Advanced Solid Tumor Malignancies

PHASE_1

Clinical Trials (1)

NCT02298387A Phase 1 Study of OMP-305B83 in Subjects With Solid Tumors

Phase 1

Help build intelligence for Mereo BioPharma

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Exposure to diverse therapeutic areas (oncology, women's health, nephrology, respiratory) across 50+ active programs provides broad learning across drug development phases
Public company status offers equity upside and career visibility versus private biotech, with ticker MREO providing transparent performance tracking
Acquisition-focused model means exposure to deal integration, asset prioritization, and rapid development cycles—valuable skills for biotech leadership

Watch Out For

No active job openings currently posted; hiring appears stalled or paused despite 50-program pipeline, signaling organizational constraint or restructuring
Significant cash burn ($43M net loss in FY2025, $29M in FY2024) against modest $70M cash reserves suggests 18-24 month runway; no recent fundraising disclosed
Extremely early-stage portfolio (30 Phase 1 programs, only 1 Phase 3) with no marketed drugs or near-term revenue catalysts; 95% of pipeline is exploratory-stage

Generated by Claude from Mereo BioPharma's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

OMP-305B83

Cancer Ovaries

PHASE_1

Clinical Trials (1)

NCT03030287A Phase 1b Study of OMP-305B83 Plus Paclitaxel in Subjects With Ovarian, Peritoneal or Fallopian Tube Cancer

Phase 1

OMP-54F28, Paclitaxel and Carboplatin

Ovarian Cancer

PHASE_1

Clinical Trials (1)

NCT02092363Dose Escalation Study of OMP-54F28 in Combination With Paclitaxel and Carboplatin in Patients With Recurrent Platinum-Sensitive Ovarian Cancer

Phase 1

Demcizumab

Pancreatic Cancer

PHASE_1

Clinical Trials (1)

NCT01189929A Study of Gemcitabine and Demcizumab (OMP-21M18) With or Without Abraxane® as 1st-line Treatment in Subjects With Locally Advanced or Metastatic Pancreatic Cancer

Phase 1

Docetaxel

Solid Tumors

PHASE_1

Clinical Trials (1)

NCT01957007A Study of Vantictumab (OMP-18R5) in Combination With Docetaxel in Patients With Previously Treated NSCLC

Phase 1

OMP-18R5

Solid Tumors

PHASE_1

Clinical Trials (1)

NCT01345201A Dose Escalation Study of OMP-18R5 in Subjects With Solid Tumors

Phase 1

OMP-21M18

Colorectal Cancer

PHASE_1

Clinical Trials (1)

NCT01189942A Study of FOLFIRI Plus OMP-21M18 as 1st or 2nd-line Treatment in Subjects With Metastatic Colorectal Cancer

Phase 1

BCT197

Interaction

PHASE_1

Clinical Trials (1)

NCT03498170The Effect of Itraconazole on BCT197 Exposure in Healthy Male Participants

Phase 1

OMP-54F28, Nab-Paclitaxel and Gemcitabine

Pancreatic Cancer

PHASE_1

Clinical Trials (1)

NCT02050178Dose Escalation Study of OMP-54F28 in Combination With Nab-Paclitaxel and Gemcitabine in Patients With Previously Untreated Stage IV Pancreatic Cancer

Phase 1

OMP-59R5

Solid Tumors

PHASE_1

Clinical Trials (1)

NCT01277146A Dose Escalation Study of OMP-59R5 in Subjects With Solid Tumors

Phase 1

Vantictumab

Pancreatic Cancer

PHASE_1

Clinical Trials (1)

NCT02005315A Study of Vantictumab (OMP-18R5) in Combination With Nab-Paclitaxel and Gemcitabine in Previously Untreated Stage IV Pancreatic Cancer

Phase 1

OMP-54F28 with Sorafenib

Hepatocellular Cancer

PHASE_1

Clinical Trials (1)

NCT02069145Dose Escalation Study of OMP-54F28 in Combination With Sorafenib in Patients With Hepatocellular Cancer

Phase 1

BCT197

Interaction

PHASE_1

Clinical Trials (1)

NCT02926326The Effect of Azithromycin on BCT197 Exposure in Healthy Male Volunteers

Phase 1

OMP-52M51

Relapsed or Refractory Solid Tumors

PHASE_1

Clinical Trials (1)

NCT01778439A Dose Escalation Study of OMP-52M51 in Subjects With Solid Tumors

Phase 1

Demcizumab

Primary Peritoneal Carcinoma

PHASE_1

Clinical Trials (1)

NCT01952249A Study of Demcizumab Plus Paclitaxel in Subjects With Platinum Resistant Ovarian

Phase 1

OMP-54F28

Solid Tumors

PHASE_1

Clinical Trials (1)

NCT01608867A Dose Escalation Study of OMP-54F28 in Subjects With Solid Tumors

Phase 1

OMP-52M51

Relapsed or Refractory Lymphoid Malignancies

PHASE_1

Clinical Trials (1)

NCT01703572A Dose Escalation Study of OMP-52M51 in Subjects With Lymphoid Malignancies

Phase 1

Vantictumab combined with paclitaxel

Metastatic Breast Cancer

PHASE_1

Clinical Trials (1)

NCT01973309A Study of Vantictumab (OMP-18R5) in Combination With Paclitaxel in Locally Recurrent or Metastatic Breast Cancer

Phase 1

brontictuzumab

Metastatic Colorectal Cancer

PHASE_1

Clinical Trials (1)

NCT03031691A Study of Brontictuzumab With Chemotherapy for Subjects With Previously Treated Metastatic Colorectal Cancer

Phase 1

OMP-305B83

Metastatic Colorectal Cancer

PHASE_1

Clinical Trials (1)

NCT03035253A Study of OMP-305B83 in Subjects With Metastatic Colorectal Cancer

Phase 1

OMP-313M32

Locally Advanced Cancer

PHASE_1

Clinical Trials (1)

NCT03119428A Study of OMP-313M32 in Subjects With Locally Advanced or Metastatic Solid Tumors

Phase 1

OMP-336B11

Locally Advanced Malignant Neoplasm

PHASE_1

Clinical Trials (1)

NCT03295942A Study of OMP-336B11 in Subjects With Locally Advanced or Metastatic Tumors

Phase 1

OMP-21M18

Solid Tumors

PHASE_1

Clinical Trials (1)

NCT00744562A Phase 1 Dose Escalation Study of OMP-21M18 in Subjects With Solid Tumors

Phase 1

OMP-131R10

Advanced Relapsed Tumors

PHASE_1

Clinical Trials (1)

NCT02482441A Phase 1a/b Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of OMP-131R10

Phase 1

Demcizumab

Non Small Cell Lung Cancer

PHASE_1

Clinical Trials (1)

NCT01189968A Study of Carboplatin and Pemetrexed Plus Demcizumab (OMP-21M18) in Subjects With Non-Squamous Non-Small Cell Lung Cancer

Phase 1

Etigilimab

Solid Tumor, Adult

PHASE_1_2

Clinical Trials (1)

NCT04761198A Study of Etigilimab and Nivolumab in Participants With Locally Advanced or Metastatic Tumors

Phase 1/2

MPH966

Hematologic Malignancy

PHASE_1_2

Clinical Trials (1)

NCT03986086MPH966 for Prevention of Graft-versus-host Disease After Allogeneic Hematopoietic Stem Cell Transplantation

Phase 1/2

OMP-59R5

Stage IV Small Cell Lung Cancer

PHASE_1_2

Clinical Trials (1)

NCT01859741A Phase 1b/2 Study of OMP-59R5 (Tarextumab) in Combination With Etoposide and Platinum Therapy

Phase 1/2

Alvelestat

Covid19

PHASE_1_2

Clinical Trials (1)

NCT04539795COVID-19 Study of Safety and Tolerability of Alvelestat

Phase 1/2

OMP-59R5

Stage IV Pancreatic Cancer

PHASE_1_2

Clinical Trials (1)

NCT01647828A Phase 1b/2 Study of OMP-59R5 (Tarextumab) in Combination With Nab-Paclitaxel and Gemcitabine in Subjects With Previously Untreated Stage IV Pancreatic Cancer

Phase 1/2

BCT197

Pulmonary Disease, Chronic Obstructive

PHASE_2

Clinical Trials (1)

NCT02700919Efficacy and Safety of BCT197 in Subjects With Acute Respiratory Exacerbations of Chronic Obstructive Pulmonary Disease

Phase 2

BCT197 Part A

Acute Kidney Injury

PHASE_2

setrusumab

Osteogenesis Imperfecta, Type I

PHASE_2

Clinical Trials (1)

NCT03118570A Study in Adult Patients With Type I, III or IV Osteogenesis Imperfecta Treated With BPS804

Phase 2

BPS804

Hypophosphatasia

PHASE_2

BGS649

Hypogonadotropic Hypogonadism

PHASE_2

Clinical Trials (1)

NCT02908074A 6 Month Safety Extension Study of MBGS205

Phase 2

Active treatment with a high dose of BGS649

Endometriosis

PHASE_2

BGS649

Hypogonadotropic Hypogonadism

PHASE_2

Clinical Trials (1)

NCT02730169Safety and Efficacy of BGS649 in Male Obese Subjects With Hypogonadotropic Hypogonadism

Phase 2

Nivolumab

Ovarian Cancer

PHASE_2

Clinical Trials (1)

NCT05715216EON: A Single-arm Phase II Study of Etigilimab (OMP-313M32) in Combination With Checkpoint Inhibition (Nivolumab) in Patients With Platinum-resistant, Recurrent Epithelial Ovarian Cancer

Phase 2

BPS804

Osteogenesis Imperfecta

PHASE_2

Clinical Trials (1)

NCT03216486An Exploratory Study of BPS804 Treatment in Adult Patients With Type I, III or IV Osteogenesis Imperfecta

Phase 2

BPS804 20mg/Kg

Osteopenia

PHASE_2

Demcizumab

Pancreatic Cancer